Novartis management replaced

Novartis management replaced

TOKYO, Japan - David Epstein, president of Swiss pharmaceutical giant Novartis holds a press conference in Tokyo on April 3, 2014. The Japanese sales arm of the company, Novartis Pharma K.K., announced that its president, Yoshiyasu Ninomiya, and two other top executives have resigned to take responsibility for its employees' inappropriate involvement in a clinical study led by medical doctors.

Novartis management replaced

Novartis management replaced

TOKYO, Japan - Dirk Kosche, new president of Novartis Pharma K.K., speaks during a press conference in Tokyo on April 3, 2014. The Japanese sales arm of Swiss pharmaceutical giant Novartis announced that its president, Yoshiyasu Ninomiya, and two other top executives have resigned to take responsibility for its employees' inappropriate involvement in a clinical study led by medical doctors.

Novartis management replaced

Novartis management replaced

TOKYO, Japan - David Epstein (L), president of Swiss pharmaceutical giant Novartis speaks during a press conference in Tokyo on April 3, 2014. The Japanese sales arm of the company, Novartis Pharma K.K., announced that its president, Yoshiyasu Ninomiya, and two other top executives have resigned to take responsibility for its employees' inappropriate involvement in a clinical study led by medical doctors. At right is new Novartis Pharma K.K. President Dirk Kosche.

Novartis scandal

Novartis scandal

TOKYO, Japan - David Epstein (C), division head at Novartis AG, the Swiss-based pharmaceutical giant, and Yoshiyasu Ninomiya (R), president of Novartis Pharma K.K., a Japanese unit of Novartis AG, bow in apology during a press conference in Tokyo on Oct. 3, 2013. Novartis Pharma K.K. has allegedly engaged in deceptive advertizing for the blood pressure-lowering drug Diovan by citing a study based on manipulated clinical data.

Novartis scandal

Novartis scandal

TOKYO, Japan - David Epstein (L), division head at Novartis AG, the Swiss-based pharmaceutical giant, speaks in a press conference in Tokyo on Oct. 3, 2013. At right is Yoshiyasu Ninomiya, president of Novartis Pharma K.K., a Japanese unit of Novartis AG. Novartis Pharma K.K. has allegedly engaged in deceptive advertizing for the blood pressure-lowering drug Diovan by citing a study based on manipulated clinical data.

Novartis Pharma

Novartis Pharma

TOKYO, Japan - Yoshiyasu Ninomiya, president of Novartis Pharma K.K., attends a press conference in Tokyo on July 29, 2013. Novartis Pharma, a Japanese unit of Swiss drug company Novartis AG, said it has found no evidence a former employee manipulated or altered clinical research data for the drugmaker's Diovan blood pressure lowering drug.